Last reviewed · How we verify
VIATORR Device Registry
The primary objective is to confirm the clinical performance and safety of the GORE® VIATORR® TIPS (Transjugular Intrahepatic Portosystemic Shunt) Endoprosthesis with Controlled Expansion throughout the device functional lifetime of 3 years in real world setting. The secondary objective is to collect information on quality of life after treatment with the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion. Additionally, data will be collected on the safety and performance of the GORE TIPS Set when utilized.
Details
| Lead sponsor | W.L.Gore & Associates |
|---|---|
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 196 |
| Start date | Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Dec 31 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Chronic Liver Disease
Interventions
- Transjugular intrahepatic portosystemic shunt
Countries
France, Italy, Austria, Germany, Spain